4.65

2.11% -0.10

After Hours: 4.64 -0.01 -0.22%

Passage Bio Inc (PASG)

Overview News Price History Option Chain Financials Discussions Forecast

Passage Bio Inc stock is traded at $4.65, with a volume of 3,756. It is down -2.11% in the last 24 hours and up +0.43% over the past month. Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Previous Close:

$4.75

Open:

$4.63

24h Volume:

3,756

Relative Volume:

0.06

Market Cap:

$14.96M

Revenue:

Net Income/Loss:

$-37.68M

P/E Ratio:

-0.3929

EPS:

-11.8364

Net Cash Flow:

$-30.65M

1W Performance:

+2.88%

1M Performance:

+0.43%

6M Performance:

-44.91%

1Y Performance:

-33.57%

1-Day Range:

$4.63

$4.8745

1-Week Range:

$4.40

$4.8745

52-Week Range:

$3.29

$20.00

Passage Bio Inc Stock (PASG) Company Profile

Name

Passage Bio Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(267) 866-0312

Address

ONE COMMERCE SQUARE, PHILADELPHIA, PA

Employee

Twitter

@passage_bio

Next Earnings Date

2026-08-11

Latest SEC Filings

PASG's Discussions on Twitter

Compare PASG vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PASG Passage Bio Inc	4.65	14.42M	0	-37.68M	-30.65M	-11.84
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Downgrade	Chardan Capital Markets	Buy → Neutral
Apr-21-26	Downgrade	TD Cowen	Buy → Hold
Apr-21-26	Downgrade	Wedbush	Outperform → Neutral
Mar-31-26	Initiated	Oppenheimer	Outperform
Feb-10-26	Resumed	Chardan Capital Markets	Buy
Nov-29-24	Resumed	Wedbush	Outperform
Sep-03-24	Initiated	Rodman & Renshaw	Buy
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral
Jul-01-21	Initiated	Raymond James	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Mar-04-21	Upgrade	Goldman	Neutral → Buy
Feb-04-21	Initiated	Guggenheim	Buy
Jan-25-21	Initiated	Wedbush	Outperform
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-11-20	Initiated	Citigroup	Neutral
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-25-20	Downgrade	Goldman	Buy → Neutral
Mar-25-20	Initiated	Chardan Capital Markets	Buy
Mar-24-20	Initiated	Cowen	Outperform
Mar-24-20	Initiated	Goldman	Buy
Mar-24-20	Initiated	JP Morgan	Overweight

View All

Passage Bio Inc Stock (PASG) Latest News

Sep 06, 2026

PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits

Sep 06, 2026

Sep 05, 2026

SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Stocktwits

Sep 05, 2026

Passage Bio stock holds steady as investors weigh gene therapy pipeline and recent losses - AD HOC NEWS

Sep 05, 2026

Sep 04, 2026

Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace

Sep 04, 2026

Sep 03, 2026

Passage Bio Amends Remix Merger, Private Financing Terms - TipRanks

Sep 03, 2026

[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan

Sep 03, 2026

Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE - TradingView

Sep 03, 2026

Remix deal would leave Passage Bio (NASDAQ: PASG) investors a small slice of the combined company - Stock Titan

Sep 03, 2026

Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - Fierce Biotech

Sep 03, 2026

Sep 02, 2026

Passage Bio stock reacts to reverse split as investors watch next steps - AD HOC NEWS

Sep 02, 2026

Aug 20, 2026

Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateTech Earnings Analysis - vinanet.vn

Aug 20, 2026

Aug 19, 2026

GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity - openpr.com

Aug 19, 2026

Aug 14, 2026

Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan

Aug 14, 2026

Passage Bio | SCHEDULE 13G/A: Others - Moomoo

Aug 14, 2026

Aug 12, 2026

PASG Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2% Share GainSpecial Dividend Alert - Vinanet

Aug 12, 2026

Aug 10, 2026

Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 10, 2026

Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade

Aug 10, 2026

Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget

Aug 10, 2026

Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView

Aug 10, 2026

PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView

Aug 10, 2026

Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan

Aug 10, 2026

Aug 07, 2026

Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView

Aug 07, 2026